IQWiG: Roche's Melanoma Combo Offers 'Minor' Benefit In Germany
This article was originally published in Scrip
Executive Summary
Genentech Inc.'s and Exelixis Inc.'s Cotellic (cobimetinib), a MEK inhibitor, has an "indication of minor added benefit", according to Germany's HTA body IQWiG.